OGN241220P15000
- 0.47
- 0.000.00%
Organon & Co Newsroom
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Goldman Sachs Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $20
Organon Gets Expanded FDA Approval for VTAMA
Organon Says Vtama Cream Approved by FDA for Atopic Dermatitis
FDA Approves VTAMA (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Express News | FDA Approves Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Organon & Co. (NYSE:OGN) Is a Favorite Amongst Institutional Investors Who Own 81%
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating, Announces Target Price $15
Organon & Co.: Martha McGarry Resigns From Board >OGN
Merck-marketed Asthma Drug Linked to Psychiatric Issues: Report
US Manufacturing Index Rises To 43, Highest Since 2020
Organon & Co To Go Ex-Dividend On November 12th, 2024 With 0.28 USD Dividend Per Share
November 10th (Eastern Time) - $Organon & Co(OGN.US)$ is trading ex-dividend on November 12th, 2024.Shareholders of record on November 12th, 2024 will receive 0.28 USD dividend per share on December 1
Looking Into Organon's Recent Short Interest
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Organon & Co Shares Are Trading Lower After the FDA Extended the Target Action Date of Its Review for the Company's Supplemental New Drug Application for Vtama Cream.
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Express News | Organon & Co - FDA Raises No Safety or Efficacy Concerns for Vtama
Express News | Organon & Co - New Target Date for Vtama Review Is March 12, 2025
Express News | Organon & Co - FDA Extends Review Date for Organon's Vtama Cream
Update on FDA Review of VTAMA (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older